Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Clinical trial NCT07522411 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07522411
- Sponsor
- BinYong Liang
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-30
- Primary completion
- 2027-12-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.